Bevacizumab in kidney cancer: new indication. Premature approval of this indication.

Abstract	Only one comparative clinical trial; major protocol modifications to improve trial results; no clear evidence of a survival benefit; too many adverse effects.
Authors
Journal	Prescrire international (Prescrire Int) Vol. 18 Issue 99 Pg. 10 (Feb 2009) ISSN: 1167-7422 [Print] France
PMID	19382401 (Publication Type: Journal Article)
Chemical References	Angiogenesis Inhibitors Antibodies, Monoclonal Interferon-alpha Vascular Endothelial Growth Factor A
Topics	Angiogenesis Inhibitors (administration & dosage, adverse effects, therapeutic use) Antibodies, Monoclonal (administration & dosage, adverse effects, therapeutic use) Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, therapeutic use) Clinical Trials as Topic Drug Approval Europe Humans Interferon-alpha (administration & dosage, adverse effects, therapeutic use) Kidney Neoplasms (drug therapy) Vascular Endothelial Growth Factor A (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!